Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab
A 49-year-old male Japanese patient was admitted to our hospital under the diagnosis of COVID-19 pneumonia. For 5 days before admission, he had experienced various symptoms, including high fever, watery diarrhea, dyspnea, and cough, and he tested positive for severe acute respiratory syndrome corona...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2571-841X/3/4/29 |
| _version_ | 1797551058461917184 |
|---|---|
| author | Yugo Ashino Haorile Chagan-Yasutan Masumitsu Hatta Yoichi Shirato Yorihiko Kyogoku Hanae Komuro Toshio Hattori |
| author_facet | Yugo Ashino Haorile Chagan-Yasutan Masumitsu Hatta Yoichi Shirato Yorihiko Kyogoku Hanae Komuro Toshio Hattori |
| author_sort | Yugo Ashino |
| collection | DOAJ |
| description | A 49-year-old male Japanese patient was admitted to our hospital under the diagnosis of COVID-19 pneumonia. For 5 days before admission, he had experienced various symptoms, including high fever, watery diarrhea, dyspnea, and cough, and he tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid. The patient is a smoker who was on medication for hypertension. A chest computed tomography scan showed bilateral multiple patchy ground-glass opacities. Despite being treated with several therapeutic agents, he still exhibited dyspnea (oxygen saturation [SpO<sub>2</sub>] in ambient air: 88%), a high fever (axillary temperature: 39 °C), and high blood pressure (148/98 mmHg). Because laboratory data revealed high levels of C-reactive protein (CRP; 2.10 mg/dL) and urinary β2-microglobulin (B2M; 33,683 µg/mL), the anti-interleukin-6 receptor antibody tocilizumab (TCZ; 400 mg) was administered intravenously. One day after injection, he was afebrile. Four days after the TCZ injection, his CRP level dropped to 0.27 mg/dL, B2M level decreased to 3817 µg/mL, and viral load became low. No adverse drug reaction due to TCZ was observed. The patient was discharged 15 days after admission. The early administration of TCZ in this patient prevented the pneumonia and kidney injury caused by COVID-19 from progressing to hyperinflammation syndrome. |
| first_indexed | 2024-03-10T15:39:21Z |
| format | Article |
| id | doaj.art-49189d74318241439489dbd0632f7c91 |
| institution | Directory Open Access Journal |
| issn | 2571-841X |
| language | English |
| last_indexed | 2024-03-10T15:39:21Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reports |
| spelling | doaj.art-49189d74318241439489dbd0632f7c912023-11-20T16:55:55ZengMDPI AGReports2571-841X2020-10-01342910.3390/reports3040029Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using TocilizumabYugo Ashino0Haorile Chagan-Yasutan1Masumitsu Hatta2Yoichi Shirato3Yorihiko Kyogoku4Hanae Komuro5Toshio Hattori6Department of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, JapanMongolian Psychosomatic Medicine Department, International Mongolian Medicine Hospital of Inner Mongolia, Hohhot 010065, ChinaDepartment of Infectious Diseases Medicine, Sendai City Hospital, Miyagi 982-8502, JapanDepartment of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, JapanDepartment of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, JapanDepartment of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, JapanDepartment of Health Science and Social Welfare, Kibi International University, Okayama 716-0018, JapanA 49-year-old male Japanese patient was admitted to our hospital under the diagnosis of COVID-19 pneumonia. For 5 days before admission, he had experienced various symptoms, including high fever, watery diarrhea, dyspnea, and cough, and he tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid. The patient is a smoker who was on medication for hypertension. A chest computed tomography scan showed bilateral multiple patchy ground-glass opacities. Despite being treated with several therapeutic agents, he still exhibited dyspnea (oxygen saturation [SpO<sub>2</sub>] in ambient air: 88%), a high fever (axillary temperature: 39 °C), and high blood pressure (148/98 mmHg). Because laboratory data revealed high levels of C-reactive protein (CRP; 2.10 mg/dL) and urinary β2-microglobulin (B2M; 33,683 µg/mL), the anti-interleukin-6 receptor antibody tocilizumab (TCZ; 400 mg) was administered intravenously. One day after injection, he was afebrile. Four days after the TCZ injection, his CRP level dropped to 0.27 mg/dL, B2M level decreased to 3817 µg/mL, and viral load became low. No adverse drug reaction due to TCZ was observed. The patient was discharged 15 days after admission. The early administration of TCZ in this patient prevented the pneumonia and kidney injury caused by COVID-19 from progressing to hyperinflammation syndrome.https://www.mdpi.com/2571-841X/3/4/29COVID-19pneumoniakidney injurytocilizumabβ2-microglobulinCRP |
| spellingShingle | Yugo Ashino Haorile Chagan-Yasutan Masumitsu Hatta Yoichi Shirato Yorihiko Kyogoku Hanae Komuro Toshio Hattori Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab Reports COVID-19 pneumonia kidney injury tocilizumab β2-microglobulin CRP |
| title | Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab |
| title_full | Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab |
| title_fullStr | Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab |
| title_full_unstemmed | Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab |
| title_short | Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab |
| title_sort | successful treatment of a covid 19 case with pneumonia and renal injury using tocilizumab |
| topic | COVID-19 pneumonia kidney injury tocilizumab β2-microglobulin CRP |
| url | https://www.mdpi.com/2571-841X/3/4/29 |
| work_keys_str_mv | AT yugoashino successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT haorilechaganyasutan successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT masumitsuhatta successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT yoichishirato successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT yorihikokyogoku successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT hanaekomuro successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab AT toshiohattori successfultreatmentofacovid19casewithpneumoniaandrenalinjuryusingtocilizumab |